COVID-19 and HIV/AIDS

Effectiveness of ART in reducing mortality- A meta-analysis

https://doi.org/10.53730/ijhs.v6nS1.6592

Authors

  • Timilsina Ramesh Department of Public Health, JNMC, KAHER, Belagavi, India
  • Sharma Shuvam Department of Public Health, JNMC, KAHER, Belagavi, India
  • Bhattarai Shubhechchha Department of Public Health, JNMC, KAHER, Belagavi, India
  • Khan Salman School of Allied Health Sciences, Noida International University, Delhi NCR, India
  • Chettri Dronesh Department of Public Health, JNMC, KAHER, Belagavi, India
  • Yadav Saroj Kumar Department of Public Health, JNMC, KAHER, Belagavi, India
  • Lachyan Abhishek Department of Social and Preventive Medicine, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
  • Ahmad Maruf School of Allied Health Sciences, Noida International University, Delhi NCR, India
  • Wani Zahid School of Allied Health Sciences, Noida International University, Delhi NCR, India
  • Prasad J B Department of Epidemiology & Biostatistics, KAHER, Belagavi, India

Keywords:

COVID-19, HIV, ART, SARS-Cov-2 , Coronavirus

Abstract

Background: Patients who are immune-compromised have a poorer outcome from most serious infections, but this may vary depending on the type of immune deficiency and the pathogens. This study is conducted to assess the effectiveness of ART in reducing mortality in HIV/AIDS patients suffering from COVID-19. Materials and Methods: Databases including PubMed, Medline and Scopus from May 2021 to June 2021were searched for studies describing effectiveness of ART in reducing mortality among HIV/AIDS and COVID-19 co-infection patients. Quality assessment of the articles was done using CEBM checklist for different study designs.486 studies were identified and only 8 were of fair and good quality. Statistical analysis was done using STATA version 16 based on random effect model. Results: Out of total study participants, above 92.2% of PLWHA were on ART therapy. ART was associated with a higher effectiveness among HIV & SARS-CoV-2 infection (Effect Size 85.41; 95% CI; 78.35-92.48). Conclusion: Findings conclude that among HIV patients receiving Anti-Retroviral Therapy and infected by COVID-19 disease, the risk of severity and mortality is comparatively less. Further investigation into the effectiveness of ART among HIV/AIDS co-infection is warranted.

Downloads

Download data is not yet available.

References

World Health Organization. Managing epidemics: key facts about major deadly diseases. World Health Organization; 2018.

Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J Med Virol. 2020;2–3.

Guo W, Ming F, Dong Y, Zhang Q, Zhang X, Mo P, Feng Y, Liang K. A survey for COVID-19 among HIV/AIDS patients in two districts of Wuhan, China. AIDS Patients in Two Districts of Wuhan, China (3/4/2020). 2020 Mar 4.

Jockusch S, Tao C, Li X, Anderson T, Chien M, Kumar S, et al. Triphosphates of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase. 2020;6–13.

Sigel K, Swartz T, Golden E, Paranjpe I, Somani S, Richter F, et al. Coronavirus 2019 and people living with human immunodeficiency virus: Outcomes for hospitalized patients in New York City. Clin Infect Dis. 2020;71(11):2933–8.

Marimuthu J, Kumar BS, Gandhi P. A. HIV and SARS CoV-2 coinfection: A retrospective, record-based, case series from South India. J Med Virol [Internet]. 2021;93(1):163–5. Available from: http://dx.doi.org/10.1002/jmv.26271

UNAIDS. FACT SHEET 2021 Global Hiv Statistics. End AIDS epidemic. 2021;(June):1–3.

Autenrieth CS, Beck EJ, Stelzle D, Mallouris C, Mahy M, Ghys P. Global and regional trends of people living with HIV aged 50 and over: Estimates and projections for 2000–2020. PLoS One. 2018;13(11):1–11.

Shalev N, Scherer M, Lasota ED, Antoniou P, Yin MT, Zucker J, et al. Clinical Characteristics and Outcomes in People Living with Human Immunodeficiency Virus Hospitalized for Coronavirus Disease 2019. Clin Infect Dis. 2020;71(16):2294–7.

Altuntas Aydin O, Kumbasar Karaosmanoglu H, Kart Yasar K. HIV/SARS-CoV-2 coinfected patients in Istanbul, Turkey. J Med Virol. 2020;92(11):2288–90.

Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, et al. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study. Ann Intern Med. 2020;173(7):536–41.

Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. Infection [Internet]. 2020;48(5):681–6. Available from: https://doi.org/10.1007/s15010-020-01438-z

Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, Villa G, Docherty A, Harrison EM, Turtle L, Openshaw P. Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study.

Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- research that is available on the COVID-19 resource centre - including this for unrestricted research re-use a. 2020;(January):19–21.

Hadi YB, Naqvi SFZ, Kupec JT, Sarwari AR. Characteristics and outcomes of COVID-19 in patients with HIV: A multicentre research network study. Aids. 2020;34(13):F3–8.

Published

26-04-2022

How to Cite

Ramesh, T., Shuvam, S., Shubhechchha, B., Salman, K., Dronesh, C., Kumar, Y. S., Abhishek, L., Maruf, A., Zahid, W., & Prasad, J. B. (2022). COVID-19 and HIV/AIDS: Effectiveness of ART in reducing mortality- A meta-analysis. International Journal of Health Sciences, 6(S1), 7418–7427. https://doi.org/10.53730/ijhs.v6nS1.6592

Issue

Section

Peer Review Articles